Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule

NCT07508618 · tracked via the Priya Life Science China tracker

Sponsor

Sir Run Run Shaw Hospital

Phase

Phase 4

Started

2026-02-09

Last updated

2026-04-02

Condition(s) studied

Persistent Atrial Fibrillation

Investigational drug(s) / intervention(s)

Qi Dong Yi Xin GranulesPlacebo

Qi Dong Yi Xin Granules: If a participant is assigned to the study group, they will receive oral Qidong Yixin Granules after atrial fibrillation ablation: one sachet each time, three times daily, for a 12-month treatment course.

Placebo: If a participant is assigned to the control group, they will receive oral placebo matching Qidong Yixin Granules after atrial fibrillation ablation: one sachet each time, three times daily, for a 12-month treatment course.

Study summary

The goal of this clinical trial is to investigate the efficacy and safety of Qidong Yixin Granules in preventing recurrence in patients after radiofrequency catheter ablation for atrial fibrillation. The main question it aims to answer is:

Can Qidong Yixin Granules reduce the recurrence rate of atrial fibrillation within 1 year in patients undergoing radiofrequency catheter ablation for atrial fibrillation?

Participants will be randomly assigned, with a 50% chance of being allocated to either the study group or the control group. Regardless of which group a participant is assigned to, researchers will administer Qidong Yixin Granules or placebo within 48 hours after catheter ablation for atrial fibrillation. Group assignment is determined by computer-generated randomization, and no individual has the authority to interfere with the allocation result.

If a participant is assigned to the study group, they will receive oral Qidong Yixin Granules after atrial fibrillation ablation: one sachet each time, three times daily, for a 12-month treatment course.

If a participant is assigned to the control group, they will receive oral placebo matching Qidong Yixin Granules after atrial fibrillation ablation: one sachet each time, three times daily, for a 12-month treatment course.

Regardless of the group assignment, all participants will attend outpatient follow-up at 1, 3, 6, 9, and 12 months postoperatively. Electrocardiography (ECG) and ambulatory electrocardiography (Holter monitoring) will be performed at 1, 3, 6, and 12 months after surgery. Transthoracic echocardiography will be conducted at 3 and 12 months postoperatively. Anticoagulation will be administered for at least 3 months after surgery, and subsequent anticoagulation strategies will be determined based on the CHA₂DS₂-VASc score.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Age 18-80 years (inclusive); * Diagnosed with non-valvular persistent atrial fibrillation, having failed at least one antiarrhythmic drug treatment, and scheduled to undergo initial ablation; * Voluntarily participate in this study and sign an informed consent form. If the subject is unable to read or sign the informed consent form due to reasons such as lack of capacity, the informed consent process must be completed and signed by their legal guardian. If the subject is unable to read the informed consent form (e.g., illiterate subjects), the informed consent process must be witnessed and signed by a witness. Exclusion Criteria: * Valvular atrial fibrillation or paroxysmal atrial fibrillation * NYHA functional class IV or LVEF \<40%, LA diameter \>55mm; * Moderate to severe left ventricular hypertrophy (wall thickness \>1.5cm); * Patients with acute coronary syndrome or requiring stent implantation * Patients with a history of cardiac surgery within the past 6 months or previous catheter ablation * Duration of atrial fibrillation ≥5 years; * Hyperthyroidism; * Patients with atrial fibrillation and cardiomyopathy; * Patients with bradyarrhythmia requiring pacemaker implantation * Known bleeding diathesis, presence of left atrial/left atrial appendage thrombus, or severe hemostasis and coagulation dysfunction * Severe hepatic or renal insufficiency ALT ≥3 × ULN or eGFR \<45 ml/min/1.73 m²; * Patients allergic to the components of the study drug; * Patients who are currently participating or have participated in other interventional clinical studies within the past 3 months. * Pregnant or lactating women, or those with an expected lifespan of \<12 months; * Other vulnerable groups, excluding the elderly/illiterate individuals, including those with mental illnesses, cognitive impairments, critically ill patients, etc * Any other reasons deemed by the investigator as unsuitable for the patient's participation in this study

Primary outcome measure(s)

The recurrence rate of atrial fibrillation — From enrollment to the end of treatment at 12 months

Trial sites (5)

Facility	City	Region	Status
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University	Hangzhou	China	Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine	Hangzhou	China	Not Yet Recruiting
The Second Affiliated Hospital Zhejiang University School of Medicine	Hangzhou	China	Not Yet Recruiting
Deqing People'S Hospital	Huzhou	China	Not Yet Recruiting
Ningbo No.2 Hospital	Ningbo	China	Not Yet Recruiting

More Sir Run Run Shaw Hospital trials in China

Evaluating the Benefits of Personalized Traditional Chinese Medicine in Postoperative Treatment for Locally Advanced Colorectal Cancer Starting soon

Evaluation of the Safety and Efficacy of a Wideband Electric Pulse Tumor Ablation System for Malignant Pulmonary Nodules Active, not recruiting

Effectiveness of Robotic Surgery for Right Colon Cancer Starting soon

The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT) Active, not recruiting

Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer Active, not recruiting

Other trials for the same condition

Pulsed Field Ablation Versus Radiofrequency Ablation: Effects of Pulmonary Vein Isolation Combined With Left Atrial Posterior Wall Isolation on Postoperative Gastric Motility in Patients With Persistent Atrial Fibrillation Starting soon

Renal Denervation Combined With Pulsed Field Ablation to Prevent Recurrence in Persistent Atrial Fibrillation Active, not recruiting

Using a Novel Balloon-shaped Large-Focal Pulsed Field Ablation Catheter in Persistent Atrial Fibrillation Active, not recruiting

EGM Guided PFA for PerAF Active, not recruiting

Optimized Ablation of the Posterior Wall in Persistent Atrial Fibrillation Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07508618 on ClinicalTrials.gov ↗ ← All trials in China